质子泵抑制剂对氯吡格雷作用机制及临床研究进展  

Advances in clinical research on the interaction between proton pump inhibitors and clopidogrel

作　　者：张勇[1,2] 余长永[1,2] 邹建军[1] 燕翔[3] 贺春晖[3] 马海涛[2] 倪斌[2] 陈绍良[4] 

机构地区：[1]南京医科大学附属南京第一医院临床药理实验室,江苏省南京市210006 [2]苏州大学附属第一医院心胸外科,江苏省苏州市215006 [3]南京医科大学药学院,江苏省南京市210029 [4]南京医科大学附属南京第一医院心内科,江苏省南京市210006

出　　处：《世界华人消化杂志》2010年第1期75-80,共6页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No30901830~~

摘　　要：氯吡格雷作为一种新型抗血小板药物,已成为冠心病抗血小板药物治疗的基石,但临床应用氯吡格雷常引起胃肠道不适或增加消化系出血风险.为了预防氯吡格雷引起的胃肠道损害事件,临床广泛合用质子泵抑制剂.但近来许多研究发现,PPIs合用氯吡格雷会增加患者心血管不良事件的风险,这引起了临床医师的普遍关注.但目前对这一现象尚无定论,本文就氯吡格雷与PPIs相互作用的机制和临床研究进展作一综述.As a new antiplatelet drug, clopidogrel is the cornerstone of drug treatment for coronary artery disease. However , clinical use of clopidogrel frequently leads to gastrointestinal injury or increases the risk of gastrointestinal bleeding. To prevent clopidogrel-associated gastrointestinal injury, concomitant proton pump inhibitors （PPIs） have been used widely in clinical practice. However, recent studies show that treatment with clopidogrel plus PPIs can increase the incidence of adverse cardiovascular events. Despite being controversial, this finding has attracted wide attention from clinicians. This article will review the recent advances in clinical research on the interaction between proton pump inhibitors and clopidogrel.

关 键 词：质子泵抑制剂 氯吡格雷 作用机制 

分 类 号：R96[医药卫生—药理学]